Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Collagen Membrane + HUC-MSCs for Chronic Nasal Septum Perforation
NCT02947191Phase 2Unknown
- Sponsor
- Chinese Academy of Sciences
- Start
- Nov 2016
- Primary completion
- Dec 2021
- Modality
- Stem Cell Therapies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of human umbilical cord mesenchymal stem cells in nasal septal perforation (NSP), sponsored by Chinese Academy of Sciences. Primary endpoint: Change of Integrity of Nasal Septum Assessed by Endoscopic Examination at 12 weeks. Status: unknown.
02
Drugs
human umbilical cord mesenchymal stem cells
03
Conditions
nasal septal perforation (NSP)
Beyond the preview
Go deeper on NCT02947191.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02947191.